Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Fig. 2

Dynamic change of plasma L858R mutation and tumor burden during EGFR-TKI treatment. a In total 80 patients, the quantity of L858R decreased to its lowest level at the time of best response to EGFR-TKI treatment, and then increased to its highest level when the disease progressed. b Using Ward’s hierarchical clustering analysis, 80 patients were classified into two groups according to their type of change. In one group, the quantity of L858R increased to its highest level at the time of disease progression (ascend group), while in the other group, the quantity of L858R did not increase and maintained a stable level as the disease progressed (stable group)

Back to article page